Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:acute_myeloid_leukemia cholangiocarcinoma |
| gptkbp:ATCCode |
L01XX59
|
| gptkbp:CASNumber |
1448347-49-6
|
| gptkbp:chemicalFormula |
C28H22ClF3N6O3
|
| gptkbp:developedBy |
gptkb:Agios_Pharmaceuticals
|
| gptkbp:genericName |
gptkb:ivosidenib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tibsovo
|
| gptkbp:indication |
newly diagnosed AML with IDH1 mutation in adults 75 years or older or with comorbidities
previously treated, locally advanced or metastatic cholangiocarcinoma with IDH1 mutation relapsed or refractory AML with IDH1 mutation |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:United_States |
| gptkbp:mechanismOfAction |
IDH1 inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue QT prolongation leukocytosis |
| gptkbp:bfsParent |
gptkb:Servier_Pharmaceuticals
gptkb:ivosidenib |
| gptkbp:bfsLayer |
7
|